Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B.
OBJECTIVE
To investigate the in vitro effect of entecavir (ETV) on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients.


METHODS
Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs were incubated with RPMI-1640 medium supplemented with fetal bovine serum, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF). DCs were treated with or without ETV on the fourth day. Cell surface molecules, including CD1a, CD80, CD83 and HLA-DR, were assessed by flow cytometry. Concentrations of IL-6 and IL-12 in the supernatant were assayed by enzyme-linked immunosorbent assay (ELISA). The ability of the generated DCs to stimulate lymphocyte proliferation was observed.


RESULTS
Compared with CHB control group, the expression levels of CD1a (29.07 +/- 3.20 vs 26.85 +/- 2.80), CD83 (25.66 +/- 3.19 vs 23.21 +/- 3.10), CD80 (28.00 +/- 2.76 vs 25.75 +/- 2.51) and HLA-DR (41.96 +/- 3.81 vs 32.20 +/- 3.04) in ETV-treated group were higher (P < 0.05). ETV-treated group secreted significantly more IL-12 (157.60 +/- 26.85 pg/mL vs 132.60 +/- 22.00 pg/mL (P < 0.05) and had a lower level of IL-6 in the culture supernatant (83.05 +/- 13.88 pg/mL vs 93.60 +/- 13.61 pg/mL, P < 0.05) than CHB control group. The ability of DCs to stimulate the proliferation of allogeneic lymphocytes was increased in ETV-treated group compared with CHB control group (1.53 +/- 0.09 vs 1.42 +/- 0.08, P < 0.05).


CONCLUSIONS
Entecavir can enhance the biological activity of DCs derived from CHB patients.
Lu
Gao-Feng
GF
Department of Gastroenterology, The Second Affiliated Hospital of Zhengzhou University, 2 Jingba Rd, Zhengzhou 450014, Henan Province, China.
Tang
Fu-Ai
FA
Zheng
Peng-Yuan
PY
Yang
Ping-Chang
PC
Qi
Yuan-Ming
YM
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D018949:Antigens, CD1 / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D018122:B7-1 Antigen / Q000378:metabolism; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects; D008562:Membrane Glycoproteins / Q000378:metabolism; D010641:Phenotype; D000097802:CD83 Antigen
D015703:Antigens, CD; D018949:Antigens, CD1; D000998:Antiviral Agents; D018122:B7-1 Antigen; D006147:Guanine; D006684:HLA-DR Antigens; D007136:Immunoglobulins; D018664:Interleukin-12; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D000097802:CD83 Antigen; C419393:CD1a antigen; C413685:entecavir